JP7386842B2 - ナフチリジン化合物およびその使用 - Google Patents

ナフチリジン化合物およびその使用 Download PDF

Info

Publication number
JP7386842B2
JP7386842B2 JP2021504235A JP2021504235A JP7386842B2 JP 7386842 B2 JP7386842 B2 JP 7386842B2 JP 2021504235 A JP2021504235 A JP 2021504235A JP 2021504235 A JP2021504235 A JP 2021504235A JP 7386842 B2 JP7386842 B2 JP 7386842B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
aryl
membered heterocyclyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021504235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531311A (ja
JP2021531311A5 (enExample
Inventor
テリー ケラー，
ジュン リャン，
シャント マルホトラ，
ロハン ヴィー． メンドンカ，
マイケル シウ，
クレイグ スティバラ，
ジョン シー． テリス，
ビンチン ウェイ，
ブライアン ケー． チャン，
ルイス ジェー． ガザード，
ティモシー ヘフロン，
グレアム ジョーンズ，
マイケル レインチベリー，
アンドリュー マディン，
アイリーン メアリー スワード，
マシュー ダブリュ． カートライト，
エマヌエラ ガンチア，
デーヴィッド フェイバー，
キン チウ フォン，
アンドリュー グッド，
ヨンハン フー，
Original Assignee
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2021531311A publication Critical patent/JP2021531311A/ja
Publication of JP2021531311A5 publication Critical patent/JP2021531311A5/ja
Application granted granted Critical
Publication of JP7386842B2 publication Critical patent/JP7386842B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021504235A 2018-07-24 2019-07-23 ナフチリジン化合物およびその使用 Active JP7386842B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018096781 2018-07-24
CNPCT/CN2018/096781 2018-07-24
PCT/US2019/043112 WO2020023551A1 (en) 2018-07-24 2019-07-23 Naphthyridine compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2021531311A JP2021531311A (ja) 2021-11-18
JP2021531311A5 JP2021531311A5 (enExample) 2022-07-22
JP7386842B2 true JP7386842B2 (ja) 2023-11-27

Family

ID=67551416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021504235A Active JP7386842B2 (ja) 2018-07-24 2019-07-23 ナフチリジン化合物およびその使用

Country Status (6)

Country Link
US (1) US12297210B2 (enExample)
EP (1) EP3826721B1 (enExample)
JP (1) JP7386842B2 (enExample)
CN (1) CN112533677A (enExample)
TW (1) TW202012405A (enExample)
WO (1) WO2020023551A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020069402A1 (en) * 2018-09-30 2020-04-02 Genentech, Inc. Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
CN116456985A (zh) * 2020-09-23 2023-07-18 深圳市原力生命科学有限公司 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法
CN114907375B (zh) * 2021-02-07 2026-03-31 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
CN114907374B (zh) * 2021-02-07 2026-03-10 苏州信诺维医药科技股份有限公司 杂环化合物、其制备方法、药物组合物及应用
MX2024000751A (es) * 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
US20240336630A1 (en) * 2021-07-15 2024-10-10 Blueprint Medicines Corporation Map4k1 inhibitors
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205942A1 (en) 2015-06-25 2016-12-29 University Health Network Hpk1 inhibitors and methods of using same
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018102366A1 (en) 2016-11-30 2018-06-07 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
JP7154221B2 (ja) 2017-03-30 2022-10-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１の阻害剤としてのナフチリジン

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN101821279A (zh) 2007-08-15 2010-09-01 赛特凯恩蒂克公司 某些化学个体、组合物和方法
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2770998B1 (en) 2011-10-27 2020-04-29 Merck Sharp & Dohme Corp. Factor ixa inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205942A1 (en) 2015-06-25 2016-12-29 University Health Network Hpk1 inhibitors and methods of using same
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018102366A1 (en) 2016-11-30 2018-06-07 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
JP7154221B2 (ja) 2017-03-30 2022-10-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１の阻害剤としてのナフチリジン

Also Published As

Publication number Publication date
EP3826721C0 (en) 2023-10-11
EP3826721A1 (en) 2021-06-02
JP2021531311A (ja) 2021-11-18
WO2020023551A1 (en) 2020-01-30
TW202012405A (zh) 2020-04-01
US20210277024A1 (en) 2021-09-09
CN112533677A (zh) 2021-03-19
US12297210B2 (en) 2025-05-13
EP3826721B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
JP7386841B2 (ja) イソキノリン化合物及びその使用
US12297210B2 (en) Naphthyridine compounds and uses thereof
JP7482118B2 (ja) 癌の治療用のイソキノリン化合物
JP7132937B2 (ja) Ｈｐｋ１の阻害剤としてのアザインドール
US11034692B1 (en) Naphthyridines as inhibitors of HPK1
JP7433304B2 (ja) シンノリン化合物および癌などのｈｐｋ１依存性障害の治療
US12208088B2 (en) Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
CA3054161A1 (en) Isoquinolines as inhibitors of hpk1
HK40042235A (en) Naphthyridine compounds and uses thereof
HK40061214A (en) Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer
HK40062959A (en) Isoquinoline compounds for the treatment of cancer
HK40015968B (en) Azaindoles as inhibitors of hpk1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220713

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231114

R150 Certificate of patent or registration of utility model

Ref document number: 7386842

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150